Police said they have made five arrests in the incident. Those arrested have been identified as Prabhjit Singh, the main accused, Kulbir Singh, Sahib Singh, Gurjant Singh and Ninder Kaur, they said.
USFDA consent decree reveals that firm will have to forego huge short-term opportunities for its generics.
Patient safety and quality our guidance now, says CEO and MD Arun Sawhney.
The US FDA, during its inspection of Ranbaxy's manufacturing facilities in India, between 2006 and 2008, had found violations, incomplete testing records and an inadequate stability programme, besides manufacturing practices that did not follow regulations.
The group is looking into a new role for Ranbaxy CEO and MD Arun Sawhney.
During the quarter, growth in base business was driven by India and Western Europe.
Shares of Ranbaxy Laboratories on Friday slumped as much as 20 per cent in the morning trade after the USFDA prohibited the company from producing and distributing drugs for the American market from its Toansa plant in Punjab.
Drug major Ranbaxy Laboratories on Thursday said it plans to launch more generic products in the US market with possible marketing exclusivity, while keeping options open for overseas acquisitions to grow its business in various global markets.
It had posted net profit of Rs 125.75 crore (Rs 1.25 billion) during the January-March quarter of the previous fiscal, 2012-13.
Company is among the few companies in the sector getting pulled up by FDA for violations at its factories in India.
.jpg)
The company has been reported to be retrenching staff.
Pharma major Ranbaxy Laboratories has set aside Rs 257.4 crore (Rs 2.57 billion) towards the financial impact of a US ban on import of products made at its plant at Toansa.
Ranbaxy Laboratories on Thursday said it will co-operate fully with any regulator from anywhere in the world wanting to investigate its manufacturing practices.
Ranbaxy Laboratories on Wednesday reported widening of its consolidated net loss to Rs 1,029.72 crore (Rs 10.29 billion) for the third quarter ended December 31, 2014
In May this year, Ranbaxy had pleaded guilty to 'felony charges' for violating manufacturing norms and agreed to pay $500 million penalty to US authorities.
'Mr Badal wanted to talk to a member of the Gandhi family to bring about some sort of rapprochement between the Akalis and the Congress which were the two major parties at that time.'
Consultants are working with various teams on manufacturing, R&D, etc, to assess per-month productivity of each department.
This year's Twenty20 World Cup could be moved to the United Arab Emirates if the COVID-19 crisis does not subside in India, the Board of Control for Cricket in India said.
"In response to India's payments data circular, we've built a system that stores payments-related data locally in India," WhatsApp spokesperson said in a statement.
A total of 16 secretaries have been appointed to various central government departments.
And when an inspector asked about the contents of unlabelled vials in the laboratory glassware washing area, a plant worker dumped them down a sink and said the contents could not be determined, according to a July 18 letter from the US Food and Drug Administration to Wockhardt, which makes sterile injectable drugs and various forms of insulin.
'A dangerous and false binary is now surfacing in Indian political discourse, which must be firmly rejected.' 'It is that we have to choose between freedom and development.' 'For us freedom is neither merely an instrument for development nor to be subordinated to development.' 'It is, as our founding fathers proclaimed early in our freedom struggle, 'our birthright' on which we shall never compromise.' 'Growth, wealth and development are fruits of democracy, not substitutes.' Dr Manmohan Singh's thoughts on democracy: A Must Read!
Business reacted with caution to the reforms of 1991, and demanded protection from multinationals and imports. Twenty-five years later, traces of that demand can still be found, reports Bhupesh Bhandari.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances